Demands for services in this sector have increased since last year’s Q1 Scientific acquisition, CDMO says.
Q1 Scientific, a provider of environmentally-controlled current good manufacturing practice (cGMP) stability storage services for the pharma, med device, and life science sectors, has opened a new 20,000 sq ft cGMP facility in Belgium, expanding its capacity for environmentally-controlled stability storage services to the aforementioned industries across Europe. The company was previously acquired by Cambrex, a contract development and manufacturing organization (CDMO) that provides drug substance, drug product, and analytical services across the entire drug lifecycle, in June of last year.
Located in the Liege region and approximately 56 miles from Brussels, the new state-of-the-art temperature-controlled and monitored storage facility provides 35,000 temperature-controlled storage spaces for various International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) climatic zones, including long-term, intermediate, and accelerated stability trials including 2–8°C, 25°C/60% relative humidity (RH) and 40°C/75% RH.
“Following our acquisition of Q1 Scientific in June 2022, we have continued to see an increase in demand for stability storage services,” comments Tom Loewald, CEO at Cambrex. “This expansion provides easily accessible capacity in continental Europe, as well as flexibility to react quickly and effectively to customers’ changing requirements.”